Evaluating the role of radiology manipulators in cancer imaging interpretation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the effectiveness of medical electroradiology manipulators (MEMs) in validating radiological work related to solid cancers using the RECIST 1.1 criteria. Patients involved in the CIMER study will undergo baseline examinations without informing the radiologists to avoid bias. The MEMs will conduct preliminary analyses of imaging results and present them to the radiologists for validation. This approach seeks to enhance the quality of radiological reports and reduce interpretation time amidst increasing workloads in oncology imaging.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female aged 18 and over
* Patient included in a clinical research protocol in oncology for solid cancer including RECIST 1.1 interpretation
* Disease measurable according to RECIST 1.1
* Patient not objecting to study participation
* Member of a social security scheme, or beneficiary of such a scheme.

Non inclusion Criteria:

* Patients with lymphoma or leukemia
* Patient contraindicated to iodinated contrast media injection
* Person in an emergency situation, adult subject to a legal protection measure (major under guardianship, curatorship or safeguard of justice), or unable to express, his/her non-opposition to participate in the study
* Unable to undergo medical follow-up for geographical, social or psychological reasons.

or psychological reasons.

Exclusion Criteria:

* Patient with renal insufficiency or allergy during the trial no longer allowing injection of iodinated contrast medium
* Patient refusing iodinated PDC injection during the study
* Patient withdrawn from the study including scanner interpretation in Recist 1.1

Where it's running

• Institut PAoli Camettes
  Marseille, Institut Paoli Calmettes, France Recruiting

Study contacts

• Study coordinator: Jihane PAKRADOUNI, Pr
• Email: pakradounij@ipc.unicancer.fr
• Phone: 0491223824

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AK138D1 for advanced solid tumors

  We will try AK138D1 given by IV in adults with advanced solid tumors that haven't responded to standard treatments to find a safe dose and see if it can shrink tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang · NCT07281326

• PRaG-1 Plus PRaG Therapy with Radiation and Immunotherapy in Older Adults with Advanced Solid Tumors

  This study tests whether giving PRaG-1 Cordycepin tablets together with radiation, immune-boosting injections, and PD-1/PD-L1 inhibitors can help people aged 65 and older with advanced solid tumors.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07267234

• Cordycepin (PRaG-1) to raise CD8+ T‑cell counts after treatment for solid tumors

  This trial will test whether PRaG-1 (cordycepin) can raise low CD8+ T‑cell counts in adults who are tumor‑free after treatment for solid cancers.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07258160

• TC-G203 treatment for GPC3-positive advanced solid tumors

  This trial will test a single-dose TC-G203 cell therapy to see if it is safe and helps adults with GPC3-positive recurrent or metastatic solid tumors who have already tried other treatments.

  Recruiting Early Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07242417

• Urolithin A (MitoPure®) with immune checkpoint inhibitors for newly diagnosed solid tumors

  This trial tests whether taking urolithin A (MitoPure®) alongside first-line immune checkpoint inhibitor therapy changes immune responses in adults with newly diagnosed solid tumors.

  Recruiting Goethe University · Frankfurt · NCT07161310

• How the CES1 liver enzyme affects capecitabine levels in people with colorectal, gastric, or esophageal cancer

  This project will see if differences in the CES1 enzyme change how capecitabine is processed and whether that affects side effects like hand‑foot syndrome in adults starting capecitabine with oxaliplatin for colorectal, gastric, or esophageal cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07114627

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.